Heat shock protein-based cancer vaccines.
The ability to duplicate the remarkable success of infectious disease vaccines in cancer, with durably robust and highly specific antitumor immune responses, has been long held as one of the keys in developing true "magic bullet" cancer therapies. This article attempts to explain why cancer vaccines have failed (so far), delineate the increasingly complex barriers that prevent the eliciting of effective antitumor immunity and examines the ability of heat shock protein-based vaccines to overcome these barriers. This article is not a definitive compendium of the huge body of relevant literature but rather focuses on the major concepts underlying active specific immunotherapy in general and heat shock protein vaccines in particular.
Lee
Kelvin P
KP
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, FL, USA. klee@med.miami.edu
Raez
Luis E
LE
Podack
Eckhard R
ER
D000938:Antigen-Presenting Cells; D019496:Cancer Vaccines / Q000737:chemistry*; D006360:Heat-Shock Proteins / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System / Q000166:cytology / Q000187:drug effects
D019496:Cancer Vaccines; D006360:Heat-Shock Proteins